Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 4/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 7/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.37 |
| ▸ | CCND1 | P24385 | 7/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.37 |
| ▸ | CDK2 | P24941 | 7/20 | 0.37 |
| ▸ | CDK1 | P06493 | 6/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.37 |
| ▸ | CDK7 | P50613 | 5/20 | 0.37 |
| ▸ | CDK9 | P50750 | 5/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036141 | 0.86 | FGFR1 (0.37) | WEE1FGFR1CDK4CCNA2CCND1 | |
| SCHEMBL13553882 | 0.85 | CDK4 (0.41) | WEE1FGFR1JAK3CDK4CCNA2 | |
| SCHEMBL15041474 | 0.84 | FGFR1 (0.38) | STK3WEE1FGFR1CDK4CCNA2 | |
| SCHEMBL14682108 | 0.82 | FGFR1 (0.36) | WEE1FGFR1CDK4CCNA2CCND1 | |
| SCHEMBL15041854 | 0.80 | GCK (0.44) | STK3WEE1FGFR1CDK4CCNA2 | |
| SCHEMBL15036089 | 0.78 | FGFR4 (0.42) | STK3WEE1FGFR1JAK2JAK3 | |
| SCHEMBL15041665 | 0.75 | ACVR1 (0.37) | WEE1FGFR1JAK2JAK3PTK2 | |
| SCHEMBL15036326 | 0.75 | CDK4 (0.43) | STK3WEE1FGFR1JAK3CDK4 | |
| SCHEMBL13553813 | 0.74 | PKN1 (0.47) | WEE1FGFR1JAK3CDK4CCNA2 | |
| SCHEMBL15041700 | 0.73 | CDK2 (0.41) | FGFR1CDK4CCNA2CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | STK3 355/4885WEE1 1354/4885FGFR1 1720/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | STK3 333/4885WEE1 545/4885FGFR1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.